In­di­a's Glen­mark Phar­ma­ceu­ti­cals di­vests 75% stake in its API man­u­fac­tur­ing sub­sidiary

Gener­ics pro­duc­er Glen­mark Phar­ma­ceu­ti­cals is di­vest­ing al­most com­plete­ly from its ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API)-man­u­fac­tur­ing sub­sidiary, sell­ing 75% of its shares to Nir­ma Lim­it­ed for $7.41 (615 In­di­an ru­pees) per share for $681.26 to­tal. Glen­mark Phar­ma moves to fo­cus on der­ma­tol­ogy, on­col­o­gy and res­pi­ra­to­ry can­di­dates.

Un­der the agree­ment, Nir­ma will make a re­quired open of­fer to share­hold­ers of the API sub­sidiary Glen­mark Life Sci­ences. In­dia-based Glen­mark Phar­ma will still own 7.84% of the API man­u­fac­tur­er af­ter the di­vest­ment. Nir­ma is an In­dia-based group of com­pa­nies that man­u­fac­tures prod­ucts rang­ing from soaps to in­jecta­bles.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER